Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ContraFect Corporation | CFRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.2318 | 0.2318 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 0.20 - 3.95 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 0.2318 | USD |
ContraFect Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 2.48M | - | - | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ContraFect News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CFRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 0.62 | 0.688 | 0.20 | 0.4443698 | 314,471 | -0.3882 | -62.61% |
1 Year | 1.86 | 3.95 | 0.20 | 1.97 | 1,733,552 | -1.63 | -87.54% |
3 Years | 427.20 | 441.60 | 0.20 | 33.29 | 1,862,327 | -426.97 | -99.95% |
5 Years | 32.00 | 1,060.00 | 0.20 | 64.29 | 1,325,108 | -31.77 | -99.28% |
ContraFect Description
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lysin exebacase has a targeted spectrum of activity, meaning that it kills specific species of Staphylococci or closely related bacteria. Its IND candidate, CF-370, targets resistant gram-negative bacteria including Pseudomonas aeruginosa (P. aeruginosa). Its advanced clinical candidate, exebacase, is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis. |